IL17A and endothelial dysfunction: Nguyen et al. (2013) evaluated IL-17 and Rho-kinase in endothelial dysfunction and hypertension and in agreement with our study, showed that IL-17 caused a threefold increase in the Rho-kinase activator RhoA, which was prevented by an IL-17 neutralizing antibody.